LNSR · XBRL financial data

LENSAR financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (LNSR's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	9,795	12,105*	10,588	12,636	13,539	16,731*	14,159	13,935	14,316	16,025*	13,428	16,495
Revenue from contracts with customers	8,271	10,501*	8,641	10,684	11,815	14,822*	12,275	12,290	12,756	14,335*	11,747	14,723
Cost of revenue	4,918	6,956*	4,924	5,823	7,273	9,623*	7,034	6,911	8,280	9,088*	7,046	6,719
Research and development	1,527	1,463*	1,444	1,348	1,202	1,335*	1,534	1,425	1,367	1,296*	1,385	1,273
Selling, general and administrative	5,117	6,374*	6,796	6,784	6,077	6,831*	11,149	11,658	12,020	10,330*	2,529	6,141
Operating income (loss)	(2,040)	(2,961)*	(2,850)	(5,280)	(1,245)	(1,290)*	(5,790)	(6,289)	(7,580)	(4,919)*	2,239	2,134
Other income (expense)	265	233*	198	160	153	149*	159	193	133	151*	145	171
Income tax expense (benefit)	0	—	0	0	0	—	0	0	0	—	0	0
Net income (loss)	2,568	(3,926)*	(2,157)	(9,043)	(1,502)	(18,702)*	(27,345)	(1,764)	(3,713)	(1,458)*	36,332	3,535
Earnings per share, basic USD per share	0.13	—	(0.19)	(0.79)	(0.13)	(1.61)*	(2.32)	(0.15)	(0.31)	(0.12)*	1.56	0.14
Earnings per share, diluted USD per share	(0.23)	—	(0.19)	(0.79)	(0.13)	(1.61)*	(2.32)	(0.15)	(0.31)	(0.12)*	0.00	0.10
Weighted average shares, basic thousands of shares	11,102	11,239*	11,387	11,451	11,604	11,628*	11,774	11,937	12,044	12,073*	12,161	12,297
Weighted average shares, diluted thousands of shares	11,956	10,385*	11,387	11,451	11,604	11,628*	11,774	11,937	12,044	12,073*	15,420	23,027

Balance sheet

CSV

Fiscal quarters (LNSR's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	24,920	20,621	13,958	8,287	10,442	16,263	19,547	7,150	7,637	12,974	12,494	13,565
Short-term investments	—	3,443	3,952	5,926	7,638	6,192	5,700	13,159	9,232	5,004	1,001	0
Accounts receivable	3,848	4,001	4,023	5,893	4,373	6,085	6,885	4,987	5,901	6,377	4,896	6,170
Inventory	17,481	15,689	17,816	17,933	14,892	11,428	15,324	19,243	20,596	21,520	23,099	24,871
Prepaid and other current assets	2,132	2,367	2,357	1,853	1,705	1,616	1,373	991	776	601	625	1,919
Total current assets	48,645	46,444	42,435	40,229	39,402	41,979	49,186	45,865	44,429	46,771	42,402	47,026
Property and equipment, net	482	679	747	716	677	664	577	609	555	505	457	445
Right-of-use asset	—	2,141	—	—	—	2,466	—	—	—	2,556	—	—
Total assets	70,853	69,585	66,134	61,406	62,019	66,297	72,959	70,414	70,204	71,430	66,223	69,558
Accounts payable	3,936	4,007	4,120	4,121	3,867	5,995	7,754	11,314	14,794	18,982	10,097	11,193
Accrued liabilities	5,457	5,717	4,180	4,262	5,800	6,807	6,910	5,726	7,894	7,771	3,904	4,728
Total current liabilities	11,011	11,632	10,446	10,366	11,678	15,003	27,174	30,090	35,725	40,574	17,799	19,640
Lease liability, non-current	1,893	1,750	1,607	1,464	1,319	2,090	1,956	1,810	2,187	1,988	1,789	1,589
Total liabilities	20,723	22,409	20,552	23,977	25,497	47,651	81,316	79,682	82,327	83,665	41,649	40,869
Accumulated deficit	(107,965)	(111,891)	(114,048)	(123,091)	(124,593)	(143,295)	(170,640)	(172,404)	(176,117)	(177,575)	(141,243)	(137,708)
Total stockholders' equity	36,383	33,429	31,835	23,645	22,738	4,862	(22,141)	(23,052)	(25,907)	(26,019)	10,790	14,905
Total liabilities and equity	70,853	69,585	66,134	61,406	62,019	66,297	72,959	70,414	70,204	71,430	66,223	69,558
Common shares outstanding (cover page) thousands of shares	11,249	11,395	11,397	11,608	11,615	11,789	11,792	11,935	11,945	12,096	12,104	12,286

Cash flows

CSV

Fiscal quarters (LNSR's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	2,568	(3,926)*	(2,157)	(9,043)	(1,502)	(18,702)*	(27,345)	(1,764)	(3,713)	(1,458)*	36,332	3,535
Stock-based compensation	1,173*	816*	652	683*	668*	662*	654	766*	850*	873*	690	347*
Net cash from operating activities	(339)*	(480)*	(5,307)	(3,778)*	3,153*	3,657*	(6,938)	(4,998)*	(3,513)*	618*	(4,271)	(127)*
Purchases of property and equipment	2*	45*	20	113*	20*	3*	6	77*	0*	0*	—	—
Net cash from investing activities	(2)*	(3,965)*	(1,226)	(2,022)*	(905)*	1,992*	531	(7,492)*	4,000*	4,245*	4,000	965*
Net cash from financing activities	(205)*	146*	(130)	129*	(93)*	172*	9,691	93*	0*	474*	(209)	233*
Net change in cash	(546)*	(4,299)*	(6,663)	(5,671)*	2,155*	5,821*	3,284	(12,397)*	487*	5,337*	(480)	1,071*

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
LENSAR	13,565	16,495	(127)*	12.3M	106.8 quarters	Q2 FY26 10-QJun 30, 2026
CVRx	64,586	15,705	(8,826)*	26.6M	7.3 quarters	Q2 FY26 10-QJun 30, 2026
TriSalus Life Sciences	46,288	11,407	(10,129)*	61.6M	4.6 quarters	Q2 FY26 10-QJun 30, 2026
KORU Medical Systems	8,288	12,045	216*	46.2M	—	Q2 FY26 10-QJun 30, 2026
Venus Concept	4,312	13,776	(4,890)*	1.9M	0.9 quarters	Q3 FY25 10-QSep 30, 2025
InfuSystem Holdings	964	36,933	6,777*	19.9M	—	Q2 FY26 10-QJun 30, 2026
Mobia Medical	177,090	13,505	(15,670)*	33.3M	11.3 quarters	Q2 FY26 10-QJun 30, 2026
Pulmonx	52,690	22,835	(3,183)*	43.6M	8.5 quarters	Q3 FY26 10-QSep 30, 2026
Neuronetics	19,197	41,568	(1,008)*	76.2M	19.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.